Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced it has entered into a non-binding letter of intent with Nanosoft Polymers as an initial step toward negotiating a services agreement supporting development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration would focus on polymer process development, analytical characterization, formulation optimization and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate.
The company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance and public company advisory services, including leadership roles with TSX Venture Exchange advisory committees. Onco said his background in capital markets and corporate finance is expected to support the company’s oncology-focused growth strategy and ongoing engagement with investors and other stakeholders.
These developments signal Onco-Innovations' commitment to advancing its pipeline, particularly ONC010, which targets solid tumors through patented technology. The collaboration with Nanosoft Polymers is crucial for preparing the candidate for clinical trials, as it addresses key aspects of drug development such as formulation and manufacturing scalability. For the biotechnology industry, this partnership underscores the importance of specialized polymer expertise in oncology drug development.
The appointment of Dave Antony adds seasoned financial leadership to guide the company through capital markets and regulatory processes. Investors may view this as a positive step toward clearer financial strategy and transparency. Antony's experience with TSX Venture Exchange committees could facilitate better navigation of public market requirements.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors.
For more information, visit the full press release at https://ibn.fm/JB4rY and the company's website at https://oncoinnovations.com/.
